Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products

Carol Marcus-Sekura, James C. Richardson, Rebecca K. Harston, Nandini Sane, Rebecca L. Sheets

1 Introduction

Biological medicinal products for both human and veterinary use and the cell substrates used for their manufacture are currently tested for bovine and porcine adventitious viruses due to the widespread use of bovine serum and porcine or bovine trypsin in cell culture. Currently, testing for bovine and porcine adventitious agents is performed in compliance with the U.S. Department of Agriculture (USDA) regulations for veterinary products as specified in the 9CFR 113 regulations (9CFR). These regulations are intended to ensure that veterinary agents of concern are not introduced into new populations of animals (e.g., into new geographic regions or into previously unexposed herds or flocks), in order to prevent veterinary epidemics and protect the U.S. cattle and swine industries. Cell-culture derived vaccines for human use were developed in the 1950’s. Since fetal calf serum and bovine or porcine trypsin were used in cell culture, the 9CFR tests developed for veterinary use to screen for viruses that can infect cattle or swine were implemented by the authorities regulating human vaccines. However, many viruses not of significant concern to the cattle and swine industry are not addressed by the 9CFR testing. Today, over half a century after cell culture-derived vaccines were initially developed, the human biologics industry is still using the methods specified in the 9CFR regulations for testing FBS and porcine trypsin. When these tests are applied to bovine and porcine-derived raw materials used to manufacture products intended for human use, they may or may not detect the most relevant agents of concern for biological products for human use. The USDA
regulations call for testing bovine serum for at least nine viruses; seven are tested specifically by immunofluorescence upon exposure and amplification in susceptible cells, and at least two more are tested by more general read-outs (hemagglutination/hemadsorption or cytopathic effect) upon exposure and amplification in susceptible cells. In addition, the USDA regulations require testing of porcine trypsin for porcine parvovirus by immunofluorescence upon exposure and amplification in susceptible cells.

In the context of the human biological industry, there are three main concerns with this approach. Firstly, it is not clear whether other known bovine or porcine viruses would likely be present in fetal bovine serum or porcine trypsin. Secondly, it has not been well considered which of these 9CFR-specified viruses have human host range. Thirdly, it has also not been systematically researched whether there are other bovine and porcine agents of equal or greater concern for human biologicals that are not specified or detected by the current testing.

To gather current relevant information to try and answer these questions, a research project was undertaken with the following goals:

1. To perform a literature search to define those viruses that could contaminate bovine and porcine raw materials used in production of human biologicals and which might pose a potential safety risk to recipients.

2. To evaluate current 9CFR testing for bovine and porcine viruses to predict whether these viruses defined as a potential risk to recipients of human biologicals can likely be detected by current 9CFR tests.

Serum and trypsin manufacturers use upstream sourcing controls and harvesting and pooling procedures to limit contamination of their products. However, these practices vary by manufacturer. In the absence of a consistent procedure for processing, the worst case in terms of potential contamination was assumed; i.e., that any virus worldwide that could contaminate bovine serum or porcine trypsin and has human host range is a potential contaminant. While this assumption is a stringent one, in fact, risk mitigation procedures can and should begin at the manufacturer of the animal-derived material and at the collection abattoirs. Regulatory agencies expect manufacturers of human biologicals to regularly audit their suppliers of serum, trypsin, and other animal-derived materials, to assure that proper risk mitigation procedures are followed.

Serum collection is a non-sterile procedure and the blood from 2500 to 3000 fetuses is used to produce a single 1500 L lot of serum [1]. Similarly, the production of porcine trypsin uses huge numbers of pancreases that are extracted to produce a lot (batch) of trypsin. One infected animal may contaminate an entire batch/lot and the sensitivity of current testing may not be adequate to detect diluted contaminants. The limitations of testing for viruses in pooled products have been amply demonstrated in the human blood industry, and introduction of the mini-pool testing approach has led to increased sensitivity of detection and thereby increased safety for human recipients of these products. An additional safety concern for bovine serum and porcine trypsin is whether equipment cleaning between processing of animal-derived material lots is adequate to prevent cross-contamination.

It should be noted that the lots of bovine serum and trypsin used to produce human biologicals are often subjected to virus removal and inactivation procedures, when the likelihood of detecting a contaminant would be higher, or whether it may occur after treatment, when detection would be significantly less likely due to the inactivation of the majority, but possibly not all, of the contaminant.

Many newer products are cell-based or utilize viral vectors and are more like traditional live-attenuated vaccines where manufacture provides less opportunity to remove/inactivate viral contaminants. There have been several well-publicized contamination events caused by bovine/porcine agents that provide the opportunity to evaluate our current virus safety approach:

- Cache Valley Virus (CVV) — fermentors from multiple manufacturers have been infected. CVV, although not typically recognized as a bovine virus, is a multispecies virus with bovine host range [2].
- Calicivirus 2117 [vesivirus] — facility contamination forced a costly facility shutdown resulting in product shortage that deprived patients of product [3].
- Multiple contaminations of fermentors with reoviruses, another virus family with wide host range [4].
- Porcine circovirus type 1 and type 2 nucleic acid contamination of live rotavirus vaccines [5,6].

Contaminations of cell cultures during production of biological products often arise when huge scale-up procedures using large quantities of bovine serum or porcine trypsin are needed, and where the sensitivity of the tests currently being used is not adequate to detect a contaminant that starts at a low-level and amplifies over the long course of cell culture. Contamination has also been detected when new testing methods are applied, such as for porcine circovirus (PCV).

It is important to recognize that direct testing of bovine serum and porcine trypsin is not the only measure in place for assuring product safety and is used in conjunction with testing for viruses in cell banks and lot-to-lot in-process testing of unprocessed bulk harvest material. However, these other tests are not designed to specifically detect bovine or porcine viruses. Additionally, for some products, removal and inactivation of viruses during purification procedures must be demonstrated. This report will focus on bovine and porcine agents and their ability to be detected by the 9CFR procedures currently in use.

2. Methods

At the start of the literature search, the following goals were developed to guide and focus the search: (i) to determine whether the seven bovine viruses specified in 9CFR 113.47 [BVDV, REO, Rabies, BTV, BAd, bovine parvovirus and BRSV] are capable of infecting humans or display human host range (e.g., by infecting human cells in culture or producing antibodies in humans), (ii) to determine if, in addition to the 7 specific bovine viruses, there are other bovine viruses that would be detected by the hemadsorption/hemagglutination and cytopathic effect (CPE) procedures in 9CFR, (iii) to identify porcine viruses (in addition to porcine parvovirus) that have human host range and that could contaminate porcine trypsin, and (iv) if additional porcine viruses were identified, to determine whether the 9CFR procedure for testing of porcine cells [9CFR113.47] would detect them.

At the outset, the pathogen search sought to identify all known vertebrate viruses with bovine or porcine host ranges [natural infection, or detection of antibodies, or ability to grow in bovine or porcine cells in culture]. The second criterion for inclusion was that each virus identified also had to have human host range, which
includes more than traditionally zoonotic viruses. Searching for zoonotic bovine and porcine viruses was assumed not to be adequate for this study because biological products are frequently injected, bypassing the normal barriers to infection. Therefore, human host range was defined by the presence of any of the following: natural infection [including laboratory accidents], detection of antibodies (with or without disease manifestation), or the ability to infect human cells in culture. These were defined as Viruses of Concern.

Literature on viruses with human host range was also analyzed for infectivity among species. Bovine viruses were analyzed for the potential to infect pigs, and porcine viruses were analyzed for the potential to infect cattle.

A conservative approach was adopted to ensure viruses posing a potential threat were not inadvertently eliminated from consideration due to uninvestigated properties. The step-wise analysis used is detailed in Fig. 1 below.

3. Results

3.1. Viruses with human host range

The first analysis step identified viruses with bovine or porcine host range and step 2 selected those viruses that also display human host range. These included documented zoonotic viruses, laboratory infections after accidental exposure, detection of antiviral antibodies, and virus infection of human cells in vitro. The virus list was then narrowed to include only viruses with bovine or porcine host range that also display human host range [Tables 1 and 2]. One difficulty was that often information was obtained in reference to a genus or group of viruses (e.g., hantaviruses) but specific information on individual viruses was lacking. Also, some viruses, such as Chikungunya and Powassan, were present in vectors (mosquitoes and ticks) that feed on cattle but no direct evidence of bovine host range could be found. A virus such as porcine lymphotropic herpesvirus (PLHV), although a concern for xenotransplantation of porcine tissues into humans, was not included in the tables since it does not meet the criteria for human host range.

Expanding the definition of human host range beyond documented zoonosis resulted in approximately a 10-fold increase in the number of viruses with bovine and porcine host range (Tables 1 and 2) that are not included in the agents currently screened by 9CFR. Many of these viruses are appropriately not of concern to the cattle and swine industry.

3.2. Potential source material contaminants

Next, viruses on the list were evaluated for their potential to contaminate source materials used to produce biological products. In the absence of direct reports of detection of a particular virus in bovine serum, reported viremia or fetal transmission were used as surrogates for predicting the potential to contaminate serum. These

---

**Fig. 1.** Schematic of Step-Wise Analysis: This process was used to identify viruses with bovine and porcine host range also exhibiting human host range, that could contaminate source materials, and that may not be detected by 9CFR testing. *Data found shows that porcine viremia is likely not predictive of pancreatitis (Section 3.2).*
### Table 1
Viruses of concern with bovine and human host range.

| Virus of concern |
|------------------|
| **Adenoviridae** |
| Bovine adenovirus BAdV-9 – Human adenovirus C [7] |
| Anelloviridae (proposed family) |
| Torque teno virus TTV [8] |
| Bornaviridae |
| Borna disease virus BDV [9–12] |
| **Bunyaviridae** |
| Crimean Congo haemorrhagic fever virus CCHF [15] |
| Hantaan virus HTNV [16–18] |
| Jamestown Canyon virus JCV [19, 20] |
| LaCrosse virus LACV [19, 21] |
| Puumala virus [18, 22] |
| Rift valley fever virus RVFV [23] |
| **Caliciviridae** |
| Bovine enterovirus BEV-1, BEV-2 [63] |
| Bovine kobuvirus BKV-1 U-1 strain [64, 65] |
| Encephalomyocarditis virus EMC [66, 67] |
| Foot and mouth disease virus FMDV [68, 69] |
| Seneca valley virus SVV [70] |
| **Parvoviridae** |
| Bovine aden-associated virus BAAV [61] |
| Bovine hokovirus BHoV [62] |
| **Picornaviridae** |
| Bovine enterovirus BEV-1, BEV-2 [63] |
| **Polymoviridae** |
| Bovine polyomavirus BPyV [71] |

### Table 1 (continued)

| Virus of concern |
|------------------|
| **Poxviridae** |
| Aracatuba virus [72] |
| Bovine papular stomatitis virus BPSV [73] |
| Cantagalo virus [74] |
| Cowpox virus [15] |
| Pseudocowpox virus PCPV [75] |
| Vaccinia virus [76] |
| **Reoviridae** |
| Banna virus BAV [77, 78] |
| Bluettongue virus BTV [79] |
| Epizootic haemorrhagic disease virus EHDV [80, 81] |
| Lao Ning virus LNv [82] |
| Reovirus [83, 84] |
| Rotavirus [65, 85, 86] |
| **Retroviridae** |
| Bovine foamy virus BFV [87] |
| Bovine leukemia virus BLY [88–90] |
| **Rhabdoviridae** |
| Bovine ephemeral fever virus BEFV [91] |
| Rabies virus [92] |
| Vesicular stomatitis virus VSV [15, 93, 94] |
| **Togaviridae** |
| Eastern equine encephalitis virus EEEV [95, 96] |
| Getah virus [97, 98] |
| Powassan virus [48, 112] |
| Tick borne encephalitis virus TBEV [113] |
| Wesselsbron virus [34] |
| West Nile virus WNV (including Kunjin) [114] |

### Table 2
Viruses of concern with porcine and human host range.

| Virus of concern |
|------------------|
| **Anelloviridae (proposed family)** |
| Torque teno virus TTV [8] |
| **Bunyaviridae** |
| Crimean Congo haemorrhagic fever virus CCHF [15] |
| Hantaan virus HTNV [16, 17] |
| Jamestown Canyon virus JCV [19, 21] |
| LaCrosse virus LCV [19, 21] |
| **Caliciviridae** |
| Bovine enterovirus BEV-1, BEV-2 [63] |
| Bovine kobuvirus BKV-1 U-1 strain [64, 65] |
| Encephalomyocarditis virus EMC [66, 67] |
| Foot and mouth disease virus FMDV [68, 69] |
| Seneca valley virus SVV [70] |
| **Parvoviridae** |
| Bovine adeno-associated virus BAAV [61] |
| Bovine hokovirus BHoV [62] |
| **Picornaviridae** |
| Bovine enterovirus BEV-1, BEV-2 [63] |
| Bovine kobuvirus BKV-1 U-1 strain [64, 65] |
| Encephalomyocarditis virus EMC [66, 67] |
| Foot and mouth disease virus FMDV [68, 69] |
| Seneca valley virus SVV [70] |
| **Polymoviridae** |
| Bovine polyomavirus BPyV [71] |
markers identify the potential to cross the placenta, to accidentally contaminate FBS. Fetal transmission was defined as actual or experimental transmission of the agent or of a closely related agent. Viremia could not be used as a surrogate for prediction of the potential to contaminate porcine trypsin since two porcine viruses reported to cause pancreatitis, transmissible gastroenteritis virus (TGEV) and porcine hemagglutinating encephalomyelitis coronavirus (PHE-CoV), were also reported not to cause viremia. Therefore, most porcine viruses with human host range were included as potential contaminants of porcine trypsin or porcine cells.

3.3. Predicted detection of viruses by 9CFR

The list of the viruses of concern was then evaluated to predict whether these viruses might be detected by 9CFR testing. For those viruses not detectable by 9CFR testing, alternative methods may need to be identified or developed. The first criterion for possible detection by 9CFR is the capability to grow in tissue culture.

3.4. Detection of bovine viruses by the 9CFR procedure

The 9CFR methods to detect bovine agents [9CFR113.53(d)] use VERO, porcine kidney (PK), and swine testicular (ST) cells. Because trypsin is known to inactivate many viruses, porcine trypsin is only tested for porcine parvovirus. The testing utilizes inoculation of cells of proven equal sensitivity to PPV for 14 days with at least 1 subculture followed by IFA for PPV.

When following the 9CFR methods for porcine cells, for example, in xenotransplantation, the cell cultures are observed for CPE and tested for hemadsorption. At the end of culture, the cells are subjected to IFA using antisera specific for six viruses:

- bovine viral diarrhea virus (BVDV)
- rabies virus
- reovirus
- porcine adenovirus
- transmissible gastroenteritis virus (TGEV)
- porcine hemagglutinating encephalomyelitis virus (PHE-CoV)

Since a 9CFR procedure exists for detection of porcine viruses for use with porcine products other than trypsin, an assessment was performed for porcine viruses in Table 2 and their ability to be detected by 9CFR testing and their ability to be detected by 9CFR testing and their ability to be detectable by 9CFR testing.

The virus list in Table 1 was analyzed for viruses reported to cause CPE, HA, or HA in VERO or ST cells. This approach permitted analysis of those bovine viruses that are not deliberately included in the 9CFR testing but have a high likelihood to be detected by 9CFR testing. The bovine viruses with human host range that are likely not to be detected by 9CFR testing are reported in Table 3. For a more conservative estimate, viruses that had documented infection of and/or isolation in the cell lines used in 9CFR testing were included. Viruses that produced CPE on VERO E6 cells, a subclone of VERO used by some testing laboratories, were also considered likely to be detected, but this would need to be confirmed through direct testing.

Isolation versus growth in the cells used in 9CFR is critical, since some adapted viruses grow readily in VERO, but original isolates are difficult to grow and cannot be isolated in VERO. Although some predictions are possible, appropriate validation that the 9CFR test can actually detect field isolates of these viruses would be critical to reliance on the 9CFR test as a valid safety test for containment of raw materials with these agents.

### 3.5. Detection of porcine viruses by the 9CFR procedure

The 9CFR methods to detect porcine agents [9CFR113.53(d)] in porcine trypsin use VERO, porcine kidney (PK), and swine testicular (ST) cells. Because trypsin is known to inactivate many viruses, porcine trypsin is only tested for porcine parvovirus. The testing utilizes inoculation of cells of proven equal sensitivity to PPV for 14 days with at least 1 subculture followed by IFA for PPV.

When following the 9CFR methods for porcine cells, for example, in xenotransplantation, the cell cultures are observed for CPE and tested for hemadsorption. At the end of culture, the cells are subjected to IFA using antisera specific for six viruses:

- bovine viral diarrhea virus (BVDV)
- rabies virus
- reovirus
- porcine adenovirus
- transmissible gastroenteritis virus (TGEV)
- porcine hemagglutinating encephalomyelitis virus (PHE-CoV)
information means that many, but not all of the porcine viruses of concern likely can be cultured in either a porcine cell line or in VERO cells. As indicated above, verification that the tests actually detect field strains in a validated assay is important. Additional viruses detectable using a 21 day 9CFR 113.47 test for porcine cells include bluetongue virus (BT), rotavirus, porcine reproductive and respiratory syndrome virus (PRRS), pseudorabies virus (PRV), JEV, swine encephalitis virus, and swine influenza [148]. The results of this analysis are incorporated in Table 5.

Since porcine cells are proposed for use in xenotransplantation, information found on porcine viruses other than PPV is also presented here. As mentioned above in 3.1, a virus such as PLHV is a concern for xenotransplantation of porcine derived tissues but does not have demonstrated human host range so is not listed in the tables but should be considered for further investigation.

3.6. Analysis by virus family

Since many viruses that were identified were closely related and virus properties are important for virus clearance using solvent/detergent or filtration, viruses were also grouped into virus families. For bovine viruses with human host range, 21 virus families are represented while for porcine viruses, 17 virus families are represented [Table 5]. Shaded boxes in the table indicate that one or more members of the virus family in the given row have the characteristic indicated in the given column heading.

3.7. Assessment of viruses that may be inactivated by trypsin

Many viruses are inactivated by the enzymatic activity of trypsin. PPV is resistant to trypsin. Other viruses, like rotaviruses, are activated by low concentrations of trypsin. The starting material for trypsin preparation [i.e., the pancreatic extract] likely contains...
other porcine pancreatic enzymes [nucleases, glycosylases, lipases, etc.] that could contribute to virus inactivation. The extent of inactivation would likely vary depending on the method used for preparation of the trypsin, and therefore the virus contamination would likely vary from one trypsin preparation and one manufacturer to another. Trypsin preparations commonly used in biologics manufacturing are prepared by fractionation and chromatographic methods that result in relatively high purity but the presence of other enzymes is possible.

4. Discussion

One of the original goals of this study was to assess whether the current 9CFR testing is sufficient to ensure the safety of human biologicals. It is clear from the analyses performed that there are gaps between those viruses predicted to be detected by the 9CFR tests and those viruses that may have human host range and thus, may be of concern as contaminants. Also, in assessing the ability to be detected by 9CFR, it became apparent that many virus strains currently in virus culture collections were originally isolated by adaptation to cell culture. The ability of virus field isolates to grow in VERO cells within the time and passage constraints of the 9CFR assay needs to be explored.

There are virus families for which one or more members would likely be detected, but other members may not. In addition, the IFA read-outs are specific for members of a virus type (e.g., within bovine adenoviruses, the IFA is performed for only one of several types). Based on our literature search, our recommendation would be to retain the current 9CFR testing regimen for testing of FBS and supplement with additional testing procedures [e.g., PCR, see below]. In terms of modifying 9CFR testing of human biologicals, one may consider removing the IFA testing of bovine parvovirus and bovine RSV. BPV is a bocavirus that is not known to exhibit human host range. However, there are two other bovine parvoviruses [BAAV and bovine hokovirus] that are of concern and unlikely to be detected in the 9CFR test, so a general test for parvoviruses may be useful. BRSV was once thought to be a single virus that infected cattle and humans but now BRSV and HRSV are known to be separate

![Table 5](image)

Table 5
Table of virus families for which one or more member of the virus family given in the row have the characteristic in the given column heading, indicated by shaded boxes.

| Virus family       | Bovine | Porcine | IFA read out in 9CFR testing |
|--------------------|--------|---------|-----------------------------|
| Viruses with HHR  | Capable of fetal transmission | May contaminate FBS | Predicted to cause CPE or HAD in 9CFR | Viruses with HHR | Predicted to cause CPE or HAD in 9CFR |
| Adenoviridae       |        |         |                             | Unknown          |                             | |
| Anelloviridae      |        |         |                             | Unknown          |                             | |
| Bornaviridae       |        |         |                             | Unknown          |                             | |
| Bunyaviridae       |        |         |                             | Unknown          |                             | |
| Caliciviridae      |        |         |                             | Unknown          |                             | |
| Circoviridae       |        |         |                             | Unknown          |                             | |
| Coronavirusvirus    |        |         |                             | Unknown          |                             | |
| Flaviviridae       |        |         |                             | Unknown          |                             | |
| Hepeviridae        |        |         |                             | Unknown          |                             | |
| Herpesvirida       |        |         |                             | Unknown          |                             | |
| Orthomyxovirida    |        |         |                             | Unknown          |                             | |
| Papillomavirida    |        |         |                             | Likely           |                             | |
| Paramyxovirida     |        |         |                             |                  |                             | |
| Parvovirida        |        |         |                             |                  |                             | |
| Picornavirida      |        |         |                             |                  |                             | |
| Polymavirida       |        |         |                             |                  |                             | |
| Poxvirida          |        |         |                             |                  |                             | |
| Reovirida          |        |         |                             |                  |                             | |
| Retrovirida        |        |         |                             |                  |                             | |
| Rhadovirida        |        |         |                             |                  |                             | |
| Togavirida         |        |         |                             | Unknown          |                             | |

Note: This is not a comprehensive list of vertebrate virus families, only bovine or porcine viruses that were considered to have human host range were analyzed.
viruses. BRSV can infect human cell lines in culture so it could be a risk for products produced in human cell lines (e.g., MRC-5, HeLa, HEK 293, PER.C6), although it is not known to cause human disease.

For testing of porcine trypsin, testing using 9CFR for porcine parvovirus should continue; however, a 21d test should be considered. For testing of other products derived from porcine cells, such as some gene therapy products, the specific testing for PHE-CoV could be removed.

Below, we provide a number of options to be implemented separately or together, regarding how to address the issue of viruses known or predicted not to be detected by current 9CFR tests but of potential concern to human health were they to contaminate human biologicals made using bovine serum or porcine trypsin.

4.1. Options

4.1.1. No change in current practices and testing

The current testing algorithm is an orthogonal approach consisting of testing raw materials directly, testing bulk products for adventitious agents, monitoring of manufacturing processes for unexpected results (e.g., fermentor failures) and evaluation of the clearance of specific viruses by the manufacturing processes. This approach seems to have, for decades, prevented contamination that could have resulted in human disease. The recent finding of PCV genomic DNA in live rotavirus vaccines is of concern for product purity and quality. Although there is no evidence that the viral DNA represents a threat to human health [6,27], PCV1 and PCV2 have been shown to infect human cells in culture [27]. In addition to the current testing algorithm, current Good Manufacturing Practices aid in ensuring product purity and quality, as well as manufacturing consistency, and as a result of these practices all of the contaminations discussed earlier, with the exception of PCV, were caught before product was released to the market.

4.1.2. Modify 9CFR testing

Regulators of human biologicals should consider whether it would be appropriate to omit tests for viruses not of concern to human health and supplement with testing for specific additional viruses, such as bunyaviruses and reoviruses in addition to reovirus type 3, which are a concern to human health.

4.1.3. Require testing of bovine sera for bovine antibodies

In addition to possible cross-contamination with bovine serum during collection, the high price of fetal calf serum has the potential to encourage deliberate dilution of FBS with bovine or newborn calf serum. Another concern is the possible deliberate spiking with serum obtained from unapproved countries of origin. Maternal antibodies do not cross the bovine placenta, so a bovine fetus should not have maternal antibodies, and instituting testing for antibodies that would not be expected to be present in the fetus could address some of this concern.

4.1.4. Require gamma irradiation of serum and/or use of recombinant trypsin or serum-free media formulations

For serum: Manufacturers should continue to be encouraged to use gamma irradiation or other highly effective inactivation procedures, or to use a serum-free process where possible/feasible. The 9CFR test protocols were written from the perspective of heat inactivation of the serum [9CFR 113.53(c)]. Gamma irradiation of serum has become the industry standard for human biologicals as recommended for FBS used in Europe [CPMP/BWP/1793/02]. Sera are usually irradiated using a dose of 20–25 kGy, while for veterinary use, the dose is recommended to be 35 kGy [128]. Some viruses are relatively insensitive to gamma irradiation and it would be important to determine how 25 kgray of gamma irradiation affected viruses of concern.

For trypsin: Manufacturers should also continue to be encouraged to use recombinant trypsin, as well as suspension production that minimizes trypsin use, whenever feasible; however, there will still be a legacy of serum and trypsin use for older cell lines and these should be thoroughly screened for virus contamination. It should be kept in mind, however, that the process for preparing recombinant trypsin must itself be considered for sources of viral contamination [149].

4.1.5. Consider incorporating the minipool concept

Commercial batches of fetal bovine serum usually consist of pooled sera collected from hundreds to >1000 animals [1]. In the human blood industry, a minipool approach is used where 6–8 units are pooled and tested prior to pooling into a larger batch for fractionation. If the minipool concept were to be incorporated for FBS, it should increase the sensitivity of the testing and help to avoid the risk of contaminating larger serum pools. One drawback to the minipool approach is that it would almost certainly increase the cost of serum, and thus, may increase the risk of black-market practices and influx of illicit serum into the industry (see discussion above about this concern).

4.1.6. Consider testing for specified additional viruses

Another possible approach would be to consider the necessity and merit of including specific testing for additional viruses not specifically categorized as bovine or porcine viruses (such as arboviruses), which can infect these animals. Additionally, consideration should be given to whether specific testing needs to be performed for more recently discovered viruses, e.g., hokovirus or circoviruses.

4.1.7. Continually monitor reports of new viruses or changes in geographic source or host range

Agents that were not believed to be of concern for cattle or swine may cross species barriers. One recent example is that of the Reston strain of Ebola virus that has been found to infect pigs in the Philippines and workers on the swine farms have seroconverted [109]. Concern also exists for agents that are not obviously productively infectious for humans or for human cells in vitro, because they may have the potential to become latent and may be oncogenic in non-host species.

4.1.8. Continue to consider geographic sources of raw materials

The geographic sources of raw materials are critical, not only because of BSE, but also for other potential contaminating agents. Viruses that are known to be present in Australia and New Zealand [which in addition to the U.S. are the main sources of fetal bovine serum] are important to review and consider. Geographic sourcing remains an important aspect of quality control for these raw materials.

4.1.9. Incorporate virus-family testing of raw materials

Grouping viruses of concern because of human host range by virus family may allow streamlining of testing of raw materials for contaminants using PCR for conserved sequences or testing for related viruses using cell lines sensitive to viruses in a particular family. As shown in Table 5, 21 virus families contain viruses with bovine host range and human host range and 17 virus families include viruses with porcine host range and human host range. Since information was often not available for each member of a family, attention should be given to groups of closely related viruses where evidence of human/porcine or human/bovine host range has been found. As a result, assays to detect closely related viruses within specific families might be of great value. Since so many bovine and porcine viruses are a potential contamination risk, addition of virus family-specific PCR assays, or other similar technology of equivalent or better sensitivity, to detect all/most members of each of the 21...
virus families that have been reported to have bovine and human host range could reduce the risk of human infection. For a virus that cannot grow readily in cell culture, a PCR-based assay for the virus may be a useful direct detection method. Once viral nucleic acids have been identified by such methods, it would still be important to demonstrate whether their presence reflects an infectious agent. See Schuermann et al. [150] for a bovine polymavirus assay where virus isolation correlated with PCR detection.

4.1.10. Consider additional in-process testing
Manufacurers who use serum or trypsin in their cell cultures or elsewhere in their processes could add an additional test to the viral screening of their unprocessed bulk. One approach to be considered would be to include an additional bovine and/or porcine cell line, as appropriate, with the in vitro testing that is already done with three or more cell lines, generally of human and monkey origin and of the species of origin of the production cell substrate. These may be useful as adjuncts and/or replacements for the 9CFR tests. Tests that are routinely used for additional testing of cell banks and end-of-production cells or unprocessed bulk samples to check for contaminating viruses include in vitro or in vivo virus screens, examination of cell sections by transmission electron microscopy (TEM), retrovirus testing (e.g., RT, PERT) and virus-specific PCR tests. New tests under development include PCR with mass spectrometry (Ibis PLEX-ID, not T5000 anymore) [151], virus microarrays (VIROCHIP) [152] and massively parallel (deep) sequencing [5,153,154]. These procedures offer promise for identification of a wider range of potential viruses and need to be carefully evaluated under field conditions for sensitivity and specificity as well as ease-of-use, time-to-results, and cost-effectiveness. As with traditional PCR, most of these methods would detect nucleic acids, without regard to whether these represent infectious viruses or not, and follow-up testing for any contaminants detected by these methods would be necessary.

4.1.11. Encourage or require evaluation of the ability of bovine or porcine viruses to propagate in the cell substrate
Another possible enhancement to the current situation would be to encourage or require that manufacturers screen their porcine viruses to propagate in the cell substrate elsewhere in their processes could add an additional test to the viral screening of their unprocessed bulk. One approach to be considered would be to include an additional bovine and/or porcine cell line, as appropriate, with the in vitro testing that is already done with three or more cell lines, generally of human and monkey origin and of the species of origin of the production cell substrate. These may be useful as adjuncts and/or replacements for the 9CFR tests. Tests that are routinely used for additional testing of cell banks and end-of-production cells or unprocessed bulk samples to check for contaminating viruses include in vitro or in vivo virus screens, examination of cell sections by transmission electron microscopy (TEM), retrovirus testing (e.g., RT, PERT) and virus-specific PCR tests. New tests under development include PCR with mass spectrometry (Ibis PLEX-ID, not T5000 anymore) [151], virus microarrays (VIROCHIP) [152] and massively parallel (deep) sequencing [5,153,154]. These procedures offer promise for identification of a wider range of potential viruses and need to be carefully evaluated under field conditions for sensitivity and specificity as well as ease-of-use, time-to-results, and cost-effectiveness. As with traditional PCR, most of these methods would detect nucleic acids, without regard to whether these represent infectious viruses or not, and follow-up testing for any contaminants detected by these methods would be necessary.

Role of the funding source
This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200400045C. Support was also provided by Biotechnology Assessment Services, Inc.

The opinions expressed are solely those of the authors and should not be taken to represent the views or official policies of the NIH/NIH/NIAID or the U.S. government.

References
[1] Jochems CEA. Use, trade and harvest of livestock sera. Department of Laboratory Animal Science, Department of Animal Sciences, Utrecht University, Wageningen Agricultural University; 1997. 64.

4.1.12. Consider use of new testing technologies
Regulators and manufacturers should consider the introduction of one or more of the new testing methodologies that have been developed in the last few years for the testing of serum and trypsin. These may be useful as adjuncts and/or replacements for the 9CFR tests. Tests that are routinely used for additional testing of cell banks and end-of-production cells or unprocessed bulk samples to check for contaminating viruses include in vitro or in vivo virus screens, examination of cell sections by transmission electron microscopy (TEM), retrovirus testing (e.g., RT, PERT) and virus-specific PCR tests. New tests under development include PCR with mass spectrometry (Ibis PLEX-ID, not T5000 anymore) [151], virus microarrays (VIROCHIP) [152] and massively parallel (deep) sequencing [5,153,154]. These procedures offer promise for identification of a wider range of potential viruses and need to be carefully evaluated under field conditions for sensitivity and specificity as well as ease-of-use, time-to-results, and cost-effectiveness. As with traditional PCR, most of these methods would detect nucleic acids, without regard to whether these represent infectious viruses or not, and follow-up testing for any contaminants detected by these methods would be necessary.

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200400045C. Support was also provided by Biotechnology Assessment Services, Inc.

The opinions expressed are solely those of the authors and should not be taken to represent the views or official policies of the NIH/NIH/NIAID or the U.S. government.
